Home » Stocks » Moderna

Moderna, Inc. (MRNA)

Stock Price: $60.23 USD -1.35 (-2.19%)
Updated Jul 9, 2020 10:31 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 23.42B
Revenue (ttm) 52.57M
Net Income (ttm) -505.59M
Shares Out 371.22M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $60.23
Previous Close $61.58
Change ($) -1.35
Change (%) -2.19%
Day's Open 62.04
Day's Range 60.07 - 62.46
Day's Volume 2,348,189
52-Week Range 11.54 - 87.00

More Stats

Market Cap 23.42B
Enterprise Value 22.35B
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 371.22M
Float 253.61M
EPS (basic) -1.49
EPS (diluted) -1.50
FCF / Share -1.28
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 22.86M
Short Ratio 0.95
Short % of Float 10.29%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 445.45
PB Ratio 13.25
Revenue 52.57M
Operating Income -534.75M
Net Income -505.59M
Free Cash Flow -451.41M
Net Cash 1.07B
Net Cash / Share 2.75
Gross Margin -829.51%
Operating Margin -1,017.16%
Profit Margin -961.70%
FCF Margin -858.64%
ROA -17.26%
ROE -32.76%
ROIC -35.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 11
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(47.77% upside)
Current: 60.23
Target: 89.00
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-55.42%-34.38%89.88%-
Gross Profit60.21135206108
Operating Income-546-413-269-224
Net Income-514-385-256-216
Shares Outstanding33181.1164.5060.75
Earnings Per Share-1.55-4.95-4.18-3.79
Operating Cash Flow-459-331-33166.73
Capital Expenditures-31.55-106-58.40-33.14
Free Cash Flow-491-437-39033.59
Cash & Equivalents1,1041,5227571,058
Total Debt13233.4915.6912.50
Net Cash / Debt9721,4897411,046
Book Value1,1751,530-551-335
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Moderna, Inc.
Country United States
Employees 850
CEO Stéphane Bancel

Stock Information

Ticker Symbol MRNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRNA
IPO Date December 7, 2018


Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.